madman
Super Moderator
Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform
RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest...
RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX®, an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone levels due to certain medical conditions, available to patients through the Hims & Hers platform in the coming months. This marks the first time Hims & Hers will offer an FDA-approved oral testosterone therapy, underscoring KYZATREX’s position as a leader in the testosterone therapy space.
Testosterone deficiency is a common but often underdiagnosed condition that can affect men’s health and quality of life. Traditional care models have not always kept pace with patient needs, with many men facing barriers such as limited awareness, delays in seeing specialists, and fragmented care. By leveraging Hims and Hers’ scale, trusted digital platform, and patient education resources, KYZATREX will now be more accessible than ever to men requiring treatment.
“This collaboration with Hims & Hers represents an important step forward in addressing the critical need for better access and care for adult men with testosterone deficiency,” said Shalin Shah, CEO of Marius Pharmaceuticals. “By combining KYZATREX, an FDA-approved oral testosterone therapy, with Hims & Hers’ ability to reach and educate millions of men, we are breaking down barriers to care and helping to ensure patients can access innovative treatment in a convenient and trusted way.”
Andrew Dudum, CEO of Hims & Hers added, “At Hims & Hers, our mission has always been to empower people with access to high-quality care and education. Collaborating with Marius to offer KYZATREX, the first FDA-approved oral testosterone therapy on our platform, allows us to continue delivering comprehensive men’s health solutions at scale. This collaboration underscores our commitment to making care more accessible, more personalized, and more effective for patients.”
KYZATREX will be available to patients through the Hims & Hers platform in the coming months as part of a private label partnership between Marius and Hims & Hers.
